Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 225

1.

NRG1 Fusions in KRAS Wild-Type Pancreatic Cancer.

Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger M, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H.

Cancer Discov. 2018 Sep;8(9):1087-1095. doi: 10.1158/2159-8290.CD-18-0036. Epub 2018 May 25.

PMID:
29802158
2.

Overcoming chemoresistance in pancreatic cancer cells: role of the bitter taste receptor T2R10.

Stern L, Giese N, Hackert T, Strobel O, Schirmacher P, Felix K, Gaida MM.

J Cancer. 2018 Feb 1;9(4):711-725. doi: 10.7150/jca.21803. eCollection 2018.

3.

Endogenous CHRNA7-ligand SLURP1 as a potential tumor suppressor and anti-nicotinic factor in pancreatic cancer.

Throm VM, Männle D, Giese T, Bauer AS, Gaida MM, Kopitz J, Bruckner T, Plaschke K, Grekova SP, Felix K, Hackert T, Giese NA, Strobel O.

Oncotarget. 2018 Jan 24;9(14):11734-11751. doi: 10.18632/oncotarget.24312. eCollection 2018 Feb 20.

4.

Combined microRNA and mRNA microfluidic TaqMan array cards for the diagnosis of malignancy of multiple types of pancreatico-biliary tumors in fine-needle aspiration material.

Gress TM, Lausser L, Schirra LR, Ortmüller L, Diels R, Kong B, Michalski CW, Hackert T, Strobel O, Giese NA, Schenk M, Lawlor RT, Scarpa A, Kestler HA, Buchholz M.

Oncotarget. 2017 Nov 21;8(64):108223-108237. doi: 10.18632/oncotarget.22601. eCollection 2017 Dec 8.

5.

Transcriptional variations in the wider peritumoral tissue environment of pancreatic cancer.

Bauer AS, Nazarov PV, Giese NA, Beghelli S, Heller A, Greenhalf W, Costello E, Muller A, Bier M, Strobel O, Hackert T, Vallar L, Scarpa A, Büchler MW, Neoptolemos JP, Kreis S, Hoheisel JD.

Int J Cancer. 2018 Mar 1;142(5):1010-1021. doi: 10.1002/ijc.31087. Epub 2017 Oct 17.

6.

HYAL2 methylation in peripheral blood as a potential marker for the detection of pancreatic cancer: a case control study.

Schott S, Yang R, Stöcker S, Canzian F, Giese N, Bugert P, Bergmann F, Strobel O, Hackert T, Sohn C, Burwinkel B.

Oncotarget. 2017 Jun 27;8(40):67614-67625. doi: 10.18632/oncotarget.18757. eCollection 2017 Sep 15.

7.

Nondestructive tissue analysis for ex vivo and in vivo cancer diagnosis using a handheld mass spectrometry system.

Zhang J, Rector J, Lin JQ, Young JH, Sans M, Katta N, Giese N, Yu W, Nagi C, Suliburk J, Liu J, Bensussan A, DeHoog RJ, Garza KY, Ludolph B, Sorace AG, Syed A, Zahedivash A, Milner TE, Eberlin LS.

Sci Transl Med. 2017 Sep 6;9(406). pii: eaan3968. doi: 10.1126/scitranslmed.aan3968.

8.

SLC22A3 polymorphisms do not modify pancreatic cancer risk, but may influence overall patient survival.

Mohelnikova-Duchonova B, Strouhal O, Hughes DJ, Holcatova I, Oliverius M, Kala Z, Campa D, Rizzato C, Canzian F, Pezzilli R, Talar-Wojnarowska R, Malecka-Panas E, Sperti C, Federico Zambon C, Pedrazzoli S, Fogar P, Milanetto AC, Capurso G, Delle Fave G, Valente R, Gazouli M, Malleo G, Teresa Lawlor R, Strobel O, Hackert T, Giese N, Vodicka P, Vodickova L, Landi S, Tavano F, Gioffreda D, Piepoli A, Pazienza V, Mambrini A, Pedata M, Cantore M, Bambi F, Ermini S, Funel N, Lemstrova R, Soucek P.

Sci Rep. 2017 Mar 8;7:43812. doi: 10.1038/srep43812.

9.

Comparison of the tumor cell secretome and patient sera for an accurate serum-based diagnosis of pancreatic ductal adenocarcinoma.

Mustafa S, Pan L, Marzoq A, Fawaz M, Sander L, Rückert F, Schrenk A, Hartl C, Uhler R, Yildirim A, Strobel O, Hackert T, Giese N, Büchler MW, Hoheisel JD, Alhamdani MS.

Oncotarget. 2017 Feb 14;8(7):11963-11976. doi: 10.18632/oncotarget.14449.

10.

Expression of DRD2 Is Increased in Human Pancreatic Ductal Adenocarcinoma and Inhibitors Slow Tumor Growth in Mice.

Jandaghi P, Najafabadi HS, Bauer AS, Papadakis AI, Fassan M, Hall A, Monast A, von Knebel Doeberitz M, Neoptolemos JP, Costello E, Greenhalf W, Scarpa A, Sipos B, Auld D, Lathrop M, Park M, Büchler MW, Strobel O, Hackert T, Giese NA, Zogopoulos G, Sangwan V, Huang S, Riazalhosseini Y, Hoheisel JD.

Gastroenterology. 2016 Dec;151(6):1218-1231. doi: 10.1053/j.gastro.2016.08.040. Epub 2016 Aug 28.

PMID:
27578530
11.

Establishment and Characterization of a Novel Cell Line, ASAN-PaCa, Derived From Human Adenocarcinoma Arising in Intraductal Papillary Mucinous Neoplasm of the Pancreas.

Heller A, Angelova AL, Bauer S, Grekova SP, Aprahamian M, Rommelaere J, Volkmar M, Janssen JW, Bauer N, Herr I, Giese T, Gaida MM, Bergmann F, Hackert T, Fritz S, Giese NA.

Pancreas. 2016 Nov;45(10):1452-1460.

PMID:
27518460
12.

Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients.

Rizzato C, Campa D, Talar-Wojnarowska R, Halloran C, Kupcinskas J, Butturini G, Mohelníková-Duchoňová B, Sperti C, Tjaden C, Ghaneh P, Hackert T, Funel N, Giese N, Tavano F, Pezzilli R, Pedata M, Pasquali C, Gazouli M, Mambrini A, Souček P, di Sebastiano P, Capurso G, Cantore M, Oliverius M, Offringa R, Małecka-Panas E, Strobel O, Scarpa A, Canzian F.

Carcinogenesis. 2016 Oct;37(10):957-64. doi: 10.1093/carcin/bgw080. Epub 2016 Aug 5.

PMID:
27497070
13.

The potential diagnostic value of serum microRNA signature in patients with pancreatic cancer.

Johansen JS, Calatayud D, Albieri V, Schultz NA, Dehlendorff C, Werner J, Jensen BV, Pfeiffer P, Bojesen SE, Giese N, Nielsen KR, Nielsen SE, Yilmaz M, Holländer NH, Andersen KK.

Int J Cancer. 2016 Nov 15;139(10):2312-24. doi: 10.1002/ijc.30291. Epub 2016 Aug 16.

14.

Early Epigenetic Downregulation of microRNA-192 Expression Promotes Pancreatic Cancer Progression.

Botla SK, Savant S, Jandaghi P, Bauer AS, Mücke O, Moskalev EA, Neoptolemos JP, Costello E, Greenhalf W, Scarpa A, Gaida MM, Büchler MW, Strobel O, Hackert T, Giese NA, Augustin HG, Hoheisel JD.

Cancer Res. 2016 Jul 15;76(14):4149-59. doi: 10.1158/0008-5472.CAN-15-0390. Epub 2016 May 23.

15.

CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.

Noll EM, Eisen C, Stenzinger A, Espinet E, Muckenhuber A, Klein C, Vogel V, Klaus B, Nadler W, Rösli C, Lutz C, Kulke M, Engelhardt J, Zickgraf FM, Espinosa O, Schlesner M, Jiang X, Kopp-Schneider A, Neuhaus P, Bahra M, Sinn BV, Eils R, Giese NA, Hackert T, Strobel O, Werner J, Büchler MW, Weichert W, Trumpp A, Sprick MR.

Nat Med. 2016 Mar;22(3):278-87. doi: 10.1038/nm.4038. Epub 2016 Feb 8.

16.

Isolation and culture of primary human pancreatic stellate cells that reflect the context of their tissue of origin.

Strobel O, Dadabaeva N, Felix K, Hackert T, Giese NA, Jesenofsky R, Werner J.

Langenbecks Arch Surg. 2016 Feb;401(1):89-97. doi: 10.1007/s00423-015-1343-6. Epub 2015 Dec 29.

PMID:
26712717
17.

Utilisation of antibody microarrays for the selection of specific and informative antibodies from recombinant library binders of unknown quality.

Kibat J, Schirrmann T, Knape MJ, Helmsing S, Meier D, Hust M, Schröder C, Bertinetti D, Winter G, Pardes K, Funk M, Vala A, Giese N, Herberg FW, Dübel S, Hoheisel JD.

N Biotechnol. 2016 Sep 25;33(5 Pt A):574-81. doi: 10.1016/j.nbt.2015.12.003. Epub 2015 Dec 17.

18.

PLAC8 Localizes to the Inner Plasma Membrane of Pancreatic Cancer Cells and Regulates Cell Growth and Disease Progression through Critical Cell-Cycle Regulatory Pathways.

Kaistha BP, Lorenz H, Schmidt H, Sipos B, Pawlak M, Gierke B, Kreider R, Lankat-Buttgereit B, Sauer M, Fiedler L, Krattenmacher A, Geisel B, Kraus JM, Frese KK, Kelkenberg S, Giese NA, Kestler HA, Gress TM, Buchholz M.

Cancer Res. 2016 Jan 1;76(1):96-107. doi: 10.1158/0008-5472.CAN-15-0216. Epub 2015 Dec 15.

19.

Clinical Impact of Structured Follow-up After Pancreatic Surgery.

Tjaden C, Michalski CW, Strobel O, Giese N, Hennche AK, Büchler MW, Hackert T.

Pancreas. 2016 Jul;45(6):895-9. doi: 10.1097/MPA.0000000000000564.

PMID:
26646267
20.

Selective inhibition of the p38 alternative activation pathway in infiltrating T cells inhibits pancreatic cancer progression.

Alam MS, Gaida MM, Bergmann F, Lasitschka F, Giese T, Giese NA, Hackert T, Hinz U, Hussain SP, Kozlov SV, Ashwell JD.

Nat Med. 2015 Nov;21(11):1337-43. doi: 10.1038/nm.3957. Epub 2015 Oct 19.

21.

Combinatorial treatment of CD95L and gemcitabine in pancreatic cancer cells induces apoptotic and RIP1-mediated necroptotic cell death network.

Pietkiewicz S, Eils R, Krammer PH, Giese N, Lavrik IN.

Exp Cell Res. 2015 Nov 15;339(1):1-9. doi: 10.1016/j.yexcr.2015.10.005. Epub 2015 Oct 8.

PMID:
26453936
22.

Stratification of pancreatic tissue samples for molecular studies: RNA-based cellular annotation procedure.

Heller A, Gaida MM, Männle D, Giese T, Scarpa A, Neoptolemos JP, Hackert T, Strobel O, Hoheisel JD, Giese NA, Bauer AS.

Pancreatology. 2015 Jul-Aug;15(4):423-31. doi: 10.1016/j.pan.2015.05.480. Epub 2015 Jun 15.

23.

Consensus guidelines for the detection of immunogenic cell death.

Kepp O, Senovilla L, Vitale I, Vacchelli E, Adjemian S, Agostinis P, Apetoh L, Aranda F, Barnaba V, Bloy N, Bracci L, Breckpot K, Brough D, Buqué A, Castro MG, Cirone M, Colombo MI, Cremer I, Demaria S, Dini L, Eliopoulos AG, Faggioni A, Formenti SC, Fučíková J, Gabriele L, Gaipl US, Galon J, Garg A, Ghiringhelli F, Giese NA, Guo ZS, Hemminki A, Herrmann M, Hodge JW, Holdenrieder S, Honeychurch J, Hu HM, Huang X, Illidge TM, Kono K, Korbelik M, Krysko DV, Loi S, Lowenstein PR, Lugli E, Ma Y, Madeo F, Manfredi AA, Martins I, Mavilio D, Menger L, Merendino N, Michaud M, Mignot G, Mossman KL, Multhoff G, Oehler R, Palombo F, Panaretakis T, Pol J, Proietti E, Ricci JE, Riganti C, Rovere-Querini P, Rubartelli A, Sistigu A, Smyth MJ, Sonnemann J, Spisek R, Stagg J, Sukkurwala AQ, Tartour E, Thorburn A, Thorne SH, Vandenabeele P, Velotti F, Workenhe ST, Yang H, Zong WX, Zitvogel L, Kroemer G, Galluzzi L.

Oncoimmunology. 2014 Dec 13;3(9):e955691. eCollection 2014 Oct. Review.

24.

TERT gene harbors multiple variants associated with pancreatic cancer susceptibility.

Campa D, Rizzato C, Stolzenberg-Solomon R, Pacetti P, Vodicka P, Cleary SP, Capurso G, Bueno-de-Mesquita HB, Werner J, Gazouli M, Butterbach K, Ivanauskas A, Giese N, Petersen GM, Fogar P, Wang Z, Bassi C, Ryska M, Theodoropoulos GE, Kooperberg C, Li D, Greenhalf W, Pasquali C, Hackert T, Fuchs CS, Mohelnikova-Duchonova B, Sperti C, Funel N, Dieffenbach AK, Wareham NJ, Buring J, Holcátová I, Costello E, Zambon CF, Kupcinskas J, Risch HA, Kraft P, Bracci PM, Pezzilli R, Olson SH, Sesso HD, Hartge P, Strobel O, Małecka-Panas E, Visvanathan K, Arslan AA, Pedrazzoli S, Souček P, Gioffreda D, Key TJ, Talar-Wojnarowska R, Scarpa A, Mambrini A, Jacobs EJ, Jamroziak K, Klein A, Tavano F, Bambi F, Landi S, Austin MA, Vodickova L, Brenner H, Chanock SJ, Delle Fave G, Piepoli A, Cantore M, Zheng W, Wolpin BM, Amundadottir LT, Canzian F.

Int J Cancer. 2015 Nov 1;137(9):2175-83. doi: 10.1002/ijc.29590. Epub 2015 Jun 19.

25.

Association of angiogenic factors with prognosis in esophageal cancer.

Dreikhausen L, Blank S, Sisic L, Heger U, Weichert W, Jäger D, Bruckner T, Giese N, Grenacher L, Falk C, Ott K, Schmidt T.

BMC Cancer. 2015 Mar 13;15:121. doi: 10.1186/s12885-015-1120-5.

26.

Aspirin counteracts cancer stem cell features, desmoplasia and gemcitabine resistance in pancreatic cancer.

Zhang Y, Liu L, Fan P, Bauer N, Gladkich J, Ryschich E, Bazhin AV, Giese NA, Strobel O, Hackert T, Hinz U, Gross W, Fortunato F, Herr I.

Oncotarget. 2015 Apr 30;6(12):9999-10015.

27.

Angiogenic and growth factors in gastric cancer.

Blank S, Deck C, Dreikhausen L, Weichert W, Giese N, Falk C, Schmidt T, Ott K.

J Surg Res. 2015 Apr;194(2):420-9. doi: 10.1016/j.jss.2014.11.028. Epub 2014 Nov 26.

PMID:
25577146
28.

GHSR DNA hypermethylation is a common epigenetic alteration of high diagnostic value in a broad spectrum of cancers.

Moskalev EA, Jandaghi P, Fallah M, Manoochehri M, Botla SK, Kolychev OV, Nikitin EA, Bubnov VV, von Knebel Doeberitz M, Strobel O, Hackert T, Büchler MW, Giese N, Bauer A, Muley T, Warth A, Schirmacher P, Haller F, Hoheisel JD, Riazalhosseini Y.

Oncotarget. 2015 Feb 28;6(6):4418-27.

29.

Salinomycin inhibits growth of pancreatic cancer and cancer cell migration by disruption of actin stress fiber integrity.

Schenk M, Aykut B, Teske C, Giese NA, Weitz J, Welsch T.

Cancer Lett. 2015 Mar 28;358(2):161-169. doi: 10.1016/j.canlet.2014.12.037. Epub 2014 Dec 18.

PMID:
25529011
30.

Combined evaluation of a panel of protein and miRNA serum-exosome biomarkers for pancreatic cancer diagnosis increases sensitivity and specificity.

Madhavan B, Yue S, Galli U, Rana S, Gross W, Müller M, Giese NA, Kalthoff H, Becker T, Büchler MW, Zöller M.

Int J Cancer. 2015 Jun 1;136(11):2616-27. doi: 10.1002/ijc.29324. Epub 2014 Nov 25.

31.

Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer.

Wolpin BM, Rizzato C, Kraft P, Kooperberg C, Petersen GM, Wang Z, Arslan AA, Beane-Freeman L, Bracci PM, Buring J, Canzian F, Duell EJ, Gallinger S, Giles GG, Goodman GE, Goodman PJ, Jacobs EJ, Kamineni A, Klein AP, Kolonel LN, Kulke MH, Li D, Malats N, Olson SH, Risch HA, Sesso HD, Visvanathan K, White E, Zheng W, Abnet CC, Albanes D, Andreotti G, Austin MA, Barfield R, Basso D, Berndt SI, Boutron-Ruault MC, Brotzman M, Büchler MW, Bueno-de-Mesquita HB, Bugert P, Burdette L, Campa D, Caporaso NE, Capurso G, Chung C, Cotterchio M, Costello E, Elena J, Funel N, Gaziano JM, Giese NA, Giovannucci EL, Goggins M, Gorman MJ, Gross M, Haiman CA, Hassan M, Helzlsouer KJ, Henderson BE, Holly EA, Hu N, Hunter DJ, Innocenti F, Jenab M, Kaaks R, Key TJ, Khaw KT, Klein EA, Kogevinas M, Krogh V, Kupcinskas J, Kurtz RC, LaCroix A, Landi MT, Landi S, Le Marchand L, Mambrini A, Mannisto S, Milne RL, Nakamura Y, Oberg AL, Owzar K, Patel AV, Peeters PH, Peters U, Pezzilli R, Piepoli A, Porta M, Real FX, Riboli E, Rothman N, Scarpa A, Shu XO, Silverman DT, Soucek P, Sund M, Talar-Wojnarowska R, Taylor PR, Theodoropoulos GE, Thornquist M, Tjønneland A, Tobias GS, Trichopoulos D, Vodicka P, Wactawski-Wende J, Wentzensen N, Wu C, Yu H, Yu K, Zeleniuch-Jacquotte A, Hoover R, Hartge P, Fuchs C, Chanock SJ, Stolzenberg-Solomon RS, Amundadottir LT.

Nat Genet. 2014 Sep;46(9):994-1000. doi: 10.1038/ng.3052. Epub 2014 Aug 3.

32.

Chondroitin sulfate proteoglycan CSPG4 as a novel hypoxia-sensitive marker in pancreatic tumors.

Keleg S, Titov A, Heller A, Giese T, Tjaden C, Ahmad SS, Gaida MM, Bauer AS, Werner J, Giese NA.

PLoS One. 2014 Jun 16;9(6):e100178. doi: 10.1371/journal.pone.0100178. eCollection 2014.

33.

An evidence-based systematic review of kudzu (Pueraria lobata) by the Natural Standard Research Collaboration.

Ulbricht C, Costa D, Dam C, D'Auria D, Giese N, Isaac R, LeBlanc Y, Rusie E, Weissner W, Windsor RC.

J Diet Suppl. 2015 Mar;12(1):36-104. doi: 10.3109/19390211.2014.904123. Epub 2014 May 21. Review.

PMID:
24848872
34.

An Evidence-Based Systematic Review of Goji (Lycium spp.) by the Natural Standard Research Collaboration.

Ulbricht C, Bryan JK, Costa D, Culwell S, Giese N, Isaac R, Nummy K, Pham T, Rapp C, Rusie E, Weissner W, Windsor RC, Woods J, Zhou S.

J Diet Suppl. 2015 Jun;12(2):184-240. doi: 10.3109/19390211.2014.904128. Epub 2014 May 7. Review.

PMID:
24806435
35.

Prevailing role of contact guidance in intrastromal T-cell trapping in human pancreatic cancer.

Hartmann N, Giese NA, Giese T, Poschke I, Offringa R, Werner J, Ryschich E.

Clin Cancer Res. 2014 Jul 1;20(13):3422-33. doi: 10.1158/1078-0432.CCR-13-2972. Epub 2014 Apr 24.

36.

Sulforaphane counteracts aggressiveness of pancreatic cancer driven by dysregulated Cx43-mediated gap junctional intercellular communication.

Forster T, Rausch V, Zhang Y, Isayev O, Heilmann K, Schoensiegel F, Liu L, Nessling M, Richter K, Labsch S, Nwaeburu CC, Mattern J, Gladkich J, Giese N, Werner J, Schemmer P, Gross W, Gebhard MM, Gerhauser C, Schaefer M, Herr I.

Oncotarget. 2014 Mar 30;5(6):1621-34.

37.

An evidence-based systematic review of chlorophyll by the Natural Standard Research Collaboration.

Ulbricht C, Bramwell R, Catapang M, Giese N, Isaac R, Le TD, Montalbano J, Tanguay-Colucci S, Trelour NJ, Weissner W, Windsor RC, Wortley J, Yoon H, Zeolla MM.

J Diet Suppl. 2014 Jun;11(2):198-239. doi: 10.3109/19390211.2013.859853. Review.

PMID:
24670123
38.

Complementary induction of immunogenic cell death by oncolytic parvovirus H-1PV and gemcitabine in pancreatic cancer.

Angelova AL, Grekova SP, Heller A, Kuhlmann O, Soyka E, Giese T, Aprahamian M, Bour G, Rüffer S, Cziepluch C, Daeffler L, Rommelaere J, Werner J, Raykov Z, Giese NA.

J Virol. 2014 May;88(10):5263-76. doi: 10.1128/JVI.03688-13. Epub 2014 Feb 26.

39.

Combined inhibition of Notch and JAK/STAT is superior to monotherapies and impairs pancreatic cancer progression.

Palagani V, Bozko P, El Khatib M, Belahmer H, Giese N, Sipos B, Malek NP, Plentz RR.

Carcinogenesis. 2014 Apr;35(4):859-66. doi: 10.1093/carcin/bgt394. Epub 2013 Nov 30.

PMID:
24293409
40.

An evidence-based systematic review of bitter orange (Citrus aurantium) by the Natural Standard Research Collaboration.

Ulbricht C, Costa D, Giese N, Isaac R, Liu A, Liu Y, Osho O, Poon L, Rusie E, Stock T, Weissner W, Windsor RC.

J Diet Suppl. 2013 Dec;10(4):391-431. doi: 10.3109/19390211.2013.830821. Review.

PMID:
24237193
41.

Myo-inositol trispyrophosphate-mediated hypoxia reversion controls pancreatic cancer in rodents and enhances gemcitabine efficacy.

Raykov Z, Grekova SP, Bour G, Lehn JM, Giese NA, Nicolau C, Aprahamian M.

Int J Cancer. 2014 Jun 1;134(11):2572-82. doi: 10.1002/ijc.28597. Epub 2013 Nov 25.

42.

Proteome variations in pancreatic stellate cells upon stimulation with proinflammatory factors.

Marzoq AJ, Giese N, Hoheisel JD, Alhamdani MS.

J Biol Chem. 2013 Nov 8;288(45):32517-27. doi: 10.1074/jbc.M113.488387. Epub 2013 Oct 2.

43.

An evidence-based systematic review of active hexose correlated compound (AHCC) by the Natural Standard Research Collaboration.

Ulbricht C, Brigham A, Bryan JK, Catapang M, Chowdary D, Costa D, Culwell S, D'Auria D, Giese N, Iovin R, Isaac R, Juturu V, Liu A, Mintzer M, Rusie E, Shaffer M, Windsor RC.

J Diet Suppl. 2013 Sep;10(3):264-308. doi: 10.3109/19390211.2013.822631. Epub 2013 Aug 9. Review.

PMID:
23931762
44.

Early epigenetic downregulation of WNK2 kinase during pancreatic ductal adenocarcinoma development.

Dutruel C, Bergmann F, Rooman I, Zucknick M, Weichenhan D, Geiselhart L, Kaffenberger T, Rachakonda PS, Bauer A, Giese N, Hong C, Xie H, Costello JF, Hoheisel J, Kumar R, Rehli M, Schirmacher P, Werner J, Plass C, Popanda O, Schmezer P.

Oncogene. 2014 Jun 26;33(26):3401-10. doi: 10.1038/onc.2013.312. Epub 2013 Aug 5.

PMID:
23912455
45.

Diagnostic and Prognostic Impact of Circulating YKL-40, IL-6, and CA 19.9 in Patients with Pancreatic Cancer.

Schultz NA, Christensen IJ, Werner J, Giese N, Jensen BV, Larsen O, Bjerregaard JK, Pfeiffer P, Calatayud D, Nielsen SE, Yilmaz MK, Holländer NH, Wøjdemann M, Bojesen SE, Nielsen KR, Johansen JS.

PLoS One. 2013 Jun 26;8(6):e67059. doi: 10.1371/journal.pone.0067059. Print 2013.

46.

The novel c-Met inhibitor cabozantinib overcomes gemcitabine resistance and stem cell signaling in pancreatic cancer.

Hage C, Rausch V, Giese N, Giese T, Schönsiegel F, Labsch S, Nwaeburu C, Mattern J, Gladkich J, Herr I.

Cell Death Dis. 2013 May 9;4:e627. doi: 10.1038/cddis.2013.158.

47.

Somatic mutations in exocrine pancreatic tumors: association with patient survival.

Rachakonda PS, Bauer AS, Xie H, Campa D, Rizzato C, Canzian F, Beghelli S, Greenhalf W, Costello E, Schanne M, Heller A, Scarpa A, Neoptolemos JP, Werner J, Büchler M, Hoheisel JD, Hemminki K, Giese N, Kumar R.

PLoS One. 2013;8(4):e60870. doi: 10.1371/journal.pone.0060870. Epub 2013 Apr 2.

48.

Perineural mast cells are specifically enriched in pancreatic neuritis and neuropathic pain in pancreatic cancer and chronic pancreatitis.

Demir IE, Schorn S, Schremmer-Danninger E, Wang K, Kehl T, Giese NA, Algül H, Friess H, Ceyhan GO.

PLoS One. 2013;8(3):e60529. doi: 10.1371/journal.pone.0060529. Epub 2013 Mar 28.

49.

Secretory meningiomas are defined by combined KLF4 K409Q and TRAF7 mutations.

Reuss DE, Piro RM, Jones DT, Simon M, Ketter R, Kool M, Becker A, Sahm F, Pusch S, Meyer J, Hagenlocher C, Schweizer L, Capper D, Kickingereder P, Mucha J, Koelsche C, Jäger N, Santarius T, Tarpey PS, Stephens PJ, Andrew Futreal P, Wellenreuther R, Kraus J, Lenartz D, Herold-Mende C, Hartmann C, Mawrin C, Giese N, Eils R, Collins VP, König R, Wiestler OD, Pfister SM, von Deimling A.

Acta Neuropathol. 2013 Mar;125(3):351-8. doi: 10.1007/s00401-013-1093-x. Epub 2013 Feb 12.

PMID:
23404370
50.

ABO blood groups and pancreatic cancer risk and survival: results from the PANcreatic Disease ReseArch (PANDoRA) consortium.

Rizzato C, Campa D, Pezzilli R, Soucek P, Greenhalf W, Capurso G, Talar-Wojnarowska R, Heller A, Jamroziak K, Khaw KT, Key TJ, Bambi F, Landi S, Mohelnikova-Duchonova B, Vodickova L, Büchler MW, Bugert P, Vodicka P, Neoptolemos JP, Werner J, Hoheisel JD, Bauer AS, Giese N, Canzian F.

Oncol Rep. 2013 Apr;29(4):1637-44. doi: 10.3892/or.2013.2285. Epub 2013 Feb 12.

PMID:
23403949

Supplemental Content

Support Center